London, 17 November 2025: SERB Pharmaceuticals is pleased to announce the appointment of Dr. Vignesh Rajah as its Chief Medical Officer (CMO). Dr. Rajah brings over two decades of global experience leading medical and clinical organisations in US and European pharmaceutical and biotech companies. This strategic appointment marks a significant milestone in SERB’s growth journey. […]

West Conshohocken, PA, 16 September 2025: SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on rare diseases and medical emergencies, today announced the successful completion of its acquisition of Y-mAbs Therapeutics, Inc. (“Y-mAbs”), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer. “We are excited […]

SERB Pharmaceuticals and Y-mAbs Therapeutics, Inc. have entered into a definitive merger agreement under which SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA®.